Cardioprotective effects of zofenopril, enalapril and valsartan against ischaemia/reperfusion injury as well as doxorubicin cardiotoxicity

Acta Cardiologica

Volumn 67, Issue 1, 2012, Pages 87-96

  Bozcali, Evin ^a   Dedeoglu, Deniz B ^a   Karpuz, Vildan ^b   Suzer, Oner ^a   Karpuz, Hakan ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b ISTANBUL BILIM UNIVERSITY   (Turkey)

Author keywords

Angiotensin receptor blocker; Angiotensin converting enzyme inhibitor; Antioxidants; Doxorubicin cardiotoxicity

Indexed keywords

ASPARTATE AMINOTRANSFERASE; DOXORUBICIN; ENALAPRIL; LACTATE DEHYDROGENASE; TROPONIN I; VALSARTAN; ZOFENOPRIL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BIOCHEMISTRY; BODY WEIGHT; CARDIOTOXICITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; HEART INJURY; HEART LEFT VENTRICLE EJECTION FRACTION; HEART PERFUSION; HEART PROTECTION; HEART WEIGHT; HISTOPATHOLOGY; ISCHEMIA; NONHUMAN; RAT; REPERFUSION INJURY; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION;

EID: 84857773448     PISSN: 00015385     EISSN: None     Source Type: Journal    
DOI: 10.1080/ac.67.1.2146570     Document Type: Article

References (40)

1. Berrino F, Capocaccia R, Estève J, Gatta G, Hakulinen T, Micheli A, Sant M, Verdecchia A. Survival of Cancer Patients in Europe: The EUROCARE-2 Study. Internat'RC Scientific Publications No.151. Lyon, 1999.
2. Micheli A, Mugno E, Krogh V, Quinn MJ, Coleman M, Hakulinen T, Gatta G, Berrino F, Capocaccia R and the EUROPREVAL Working Group. Cancer prevelance in European registry areas. Ann Oncol 2002; 13: 840-65.
3. Cardinale D, Colombo A, Sandri MT, Lamantia G, Colombo N, Civelli M, Martinelli G, Veglia F, Fiorentini C, Cipolla CM. Prevention of high-dose chemotherapyinduced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 2006; 114: 2474-81.
4. Yeh ETH, Tong AT, Lenihan DJ, Yusuf SW, Swafford J, Champion C, Durand JB, Gibbs H, Zafarmand AA, Ewer MS. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation 2004; 109: 3122-31.
5. Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med 1998; 339: 900-5.
6. Pacher P, Liaudet L, Bai P, Mabley JG, Kaminski PM, Virag L, Deb A, Szabó E, Ungvári Z, Wolin MS, Groves JT, Szabó C. Potent metalloporphyrin peroxynitrite decompisition catalyst protects against the development of doxorubicininduced cardiac dysfunction. Circulation 2003; 107: 896-904.
7. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin. Cancer 2003; 97: 2869-79.
8. Myers CE, McGuire WP, Liss RH, Ifrim I, Grotzinger K, Young RC. Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response. Science 1977; 197: 165-7.
9. Wang YX, Korth M. Effects of doxorubicin on excitation-contraction coupling in guinea pig ventricular myocardium. Circ Res 1995; 76: 645-53.
10. Tokarska-Schlattner M, Wallimann T, Schlattner U. Alterations in myocardial energy metabolism induced by the anti-cancer drug doxorubicin. C R Biologies 2006; 329: 657-68.
11. Sacco G, Bigioni M, Evangelista S, Goso C, Manzini S, Maggi CA. Cardioprotective effects of zofenopril, a new angiotensinconverting enzyme inhibitor, on doxorubicin-induced cardiotoxicity in the rat. Eur J Pharmacol 2001; 414: 71-8.
12. Jensen BV, Nielsen SL, Skovsgaard T. Treatment with angiotensin-convertingenzyme inhibitor for epirubicin-induced dilated cardiomyopathy. Lancet 1996; 347: 297-9.
13. Tokudome T, Mizushige K, Noma T, Manabe K, Murakami K, Tsuji T, Nozaki S, Tomohiro A, Matsuo H. Prevention of doxorubicin (adriamycin)-induced cardiomyopathy by simultaneous administration of angiotensin-converting enzyme inhibitor assessed by acoustic densitometry. J Cardiovasc Pharmacol 2000; 36: 361-8.
14. Lipshultz SE, Lipsitz SR, Sallan SE, Simbre VC 2nd, Shaikh SL, Mone SM, Gelber RD, Colan SD. Long-term enalapril therapy for left ventricular dysfunction in doxorubicintreated survivors of childhood cancer. J Clin Oncol 2002; 20: 4517-22.
15. Silber JH, Cnaan A, Clark BJ, Paridon SM, Chin AJ, Rychik J, Hogarty AN, Cohen MI, Barber G, Rutkowski M, Kimball TR, Delaat C, Steinherz LJ, Zhao H. Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines. J Clin Oncol 2004; 22: 820-8.
16. Abd El-Aziz MA, Othman AI, Amer M, El-Missiry MA. Potential protective role of angiotensin-converting enzyme inhibitors captopril and enalapril against adriamycin-induced acute cardiac and hepatic toxicity in rats. J Appl Toxicol 2001; 21: 469-73.
17. Liu X, Engelman RM, Rousou JA, Cordis GA, Das DK. Attenuation of myocardial reperfusion injury by sulfhydryl-containing angiotensin converting enzyme inhibitors. Cardiovasc Drugs Ther 1992; 6: 437-43.
18. Toko H, Oka T, Zou Y, Sakamoto M, Mizukami M, Sano M, Yamamoto R, Sugaya T, Komuro I. Angiotensin II type 1a receptor mediates doxorubicin-induced cardiomyopathy. Hypertens Res 2002; 25: 597-603.
19. Karim S, Bhandari U, Kumar H, Salam A, Siddiqui MAA, Pillai KK. Doxorubicin induced cardiotoxicity and its modulation by drugs. Indian J Pharmacol 2001; 33: 203-7.
20. Nakamae H, Tsumura K, Terada Y, Nakane T, Nakamae M, Ohta K, Yamane T, Hino M. Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone. Cancer 2005; 104: 2492-8.
21. Jugdutt BI, Menon V. Valsartan-induced cardioprotection involves angiotensin II type 2 receptor upregulation in dog and rat models of in vivo reperfused myocardial infarction. J Card Fail 2004; 10: 74-82.
22. Nishiyama A, Kobori H, Fukui T, Zhang G, Yao L, Rahman M, Hitomi H, Kiyomoto H, Shokoji T, Kimura S, Kohno M, Abe Y. Role of angiotensin II and reactive oxygen species in cyclosporine A-dependent hypertension. Hypertension 2003; 42[part 2]: 754-60.
23. Maeda A, Honda M, Kuramochi T, Tanaka K, Takabatake T. An angiotensinconverting enzyme inhibitor protects against doxorubicin-induced impairment of calcium handling in neonatal rat cardiac myocytes. Clin Exp Pharmacol Physiol 1997; 24: 720-6.
24. Chopra M, Beswick H, Clapperton M, Dargie HJ, Smith WE, McMurray J. Antioxidant effects of angiotensinconverting enzyme (ACE) inhibitors: free radical and oxidant scavenging are sulfhydryl dependent, but lipid peroxidation is inhibited by both sulfhydryl-and nonsulfhydrylcontaining ACE inhibitors. J Cardiovasc Pharmacol 1992; 19: 330-40.
25. Subissi A, Evangelista S, Giachetti, A. Preclinical profile of zofenopril: an angiotensin converting enzyme inhibitor with peculiar cardioprotective properties. Cardiovasular Drug Reviews 1999; 17: 115-33.
26. Sun Y, Mendelsohn FA. Angiotensin converting enzyme inhibition in heart, kidney, and serum studied ex vivo after administration zofenopril, captopril, and lisinopril. J Cardiovasc Pharmacol 1991; 18: 478-86.
27. Frascarelli S, Ghelardoni S, Ronca-Testoni S, Zucchi R. Cardioprotective effect of zofenopril in perfused rat heart subjected to ischemia and reperfusion. J Cardiovasc Pharmacol 2004; 43: 294-9.
28. Vasquez-Vivar J, Martasek P, Hogg N, Masters BSS, Pritchard KA, Kalyanaraman B. Endothelial nitric oxide synthase dependent superoxide generation from adriamycin. Biochemistry 1997; 36: 11293-7.
29. Qiu CB, Qiu CS, Hess P, Clozel JP, Clozel M. Additional effects of endothelin receptor blockade and angiotensin converting enzyme inhibition in rats with chronic heart failure. Acta Pharmacol Sin 2001; 22: 541-8.
30. Cardinale D, Sandri MT, Colombo A, Colombo N, Boeri M, Lamantia G, Civelli M, Peccatori F, Martinelli G, Fiorentini C, Cipolla CM. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 2004; 109: 2749-54.
31. Cardinale D, Colombo A, Sandri MT, Lamantia G, Colombo N, Civelli M, Martinelli G, Veglia F, Fiorentini C, Cipolla CM. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 2006; 114: 2474-81.
32. Cai W, Chen JZ, Ruan LM, Wang YN. Effects of fructose-1,6-diphosphate on concentration of calcium and activities of sarcoplosnic Ca2+-ATPase in cardiomyocytes of Adriamycin-treated rats. J Zhejiang Univ Sci B 2005; 6: 622-5.
33. Chocron S, Alwan K, Toubin G, Kantelip B, Clement F, Kantelip JP, Etievent JP. Effects of myocardial ischemia on the release of cardiac troponin I in isolated rat hearts. J Thorac Cardiovasc Surg 1996; 112: 508-13.
34. Bertinchant JP, Polge A, Robert E, Sabbah N, Fabbro-Peray P, Poirey S, Laprade M, Pau B, Juan JM, Bali JP, de la Coussaye JE, Dauzat M. Time-course of cardiac troponin I release from isolated perfused rat hearts during hypoxia/ reoxygenation and ischemia/reperfusion. Clin Chim Acta 1999; 283: 43-56.
35. Yang G, Fang Z, Liu Y, Zhang H, Shi X, Ji Q, Lin Q, Lin R. Protective Effects of Chinese Traditional Medicine Buyang Huanwu Decoction on Myocardial Injury. Evid Based Complement Alternat Med 2009 Feb 8. [Epub ahead of print]
36. Nousiainen T, Vanninen E, Jantunen E, Puustinen J, Remes J, Rantala A, Vuolteenaho O, Hartikainen J. Natriuretic peptides during the development of doxorubicin-induced left ventricular diastolic dysfunction. J Intern Med 2002; 251: 228-34.
37. Chen S, Garami M, Gardner DG. Doxorubicin selectively inhibits brain versus atrial natriuretic peptide gene expression in cultured neonatal rat myocytes. Hypertension 1999; 34: 1223-31.
38. Olson HM, Young DM, Prieur DJ, LeRoy AF, Reagan RL. Electrolyte and morphologic alterations of myocardium in adriamycin-treated rabbits. Am J Pathol 1974; 77: 439-54.
39. Mettler FP, Young DM, Ward JM. Adriamycin-induced cardiotoxicity (cardiomyopathy and congestive heart failure) in rats. Cancer Res 1977; 37: 2705-13.
40. Von Hoff DD, Layard MW, Basa P, Davis HL, Von Hoff AL, Rozencweig M, Muggia FM. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979; 91: 710-7.